EXPLORNA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

EXPLORNA Trademark

Serial Number: 79307984 • Registration: 6756320

EXPLORNA is a trademark filed by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA on January 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (3 trademarks)

Zwirki i Wigury 101/0.30

Entity Type: 99

Trademark Details

Filing Date

January 25, 2021

Registration Date

June 14, 2022

Published for Opposition

March 29, 2022

Goods & Services

Human vaccine preparations; vaccine adjuvants; medicinal preparations for the treatment of cancer, infectious diseases, metabolic diseases, allergic diseases, autoimmune diseases, cardiovascular diseases, diseases of the nervous system, diseases of gastrointestinal system, diseases of respiratory system, diseases of skin, diseases of secretory systems, diseases of bones and joints, diseases of hematopoietic system and animal diseases; nucleic acid sequences and chemical reagents for medical and veterinary purposes

Medical analysis for the diagnosis and treatment of persons; Medical analysis services in the nature of RNA or DNA analysis for the diagnosis and prognosis of cancer; consultancy services relating to health care; medical services in the fields of oncology, dentistry, ophthalmology, transplant medicine, infectious diseases, metabolic diseases, allergic diseases, autoimmune diseases, cardiovascular diseases, diseases of the nervous system, diseases of gastrointestinal system, diseases of respiratory system, diseases of skin, diseases of secretory systems, diseases of bones and joints, and diseases of hematopoietic system

Research and development of mRNA therapeutics; biochemical research and development; research and development of vaccines and medicines; pharmaceutical products development; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; working on and evaluation of chemical syntheses

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 14, 2022 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Oct 6, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Oct 6, 2022 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 14, 2022 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Aug 27, 2022 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 14, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 14, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 29, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 29, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Mar 27, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 10, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 9, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 9, 2022 NONP
ASSIGNED TO LIE
Feb 22, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 22, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 21, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 21, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 20, 2022 GNFN
FINAL REFUSAL E-MAILED
Feb 20, 2022 GNFR
FINAL REFUSAL WRITTEN
Feb 20, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 28, 2022 TROA
REFUSAL PROCESSED BY IB
Oct 25, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 30, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 30, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 16, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 15, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 11, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 13, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 7, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 1, 2021 REPR